Kangmei Pharmaceutical (600518 CH) - First Class Action Lawsuit in China and Its Implications

290 Views16 Nov 2021 00:06
Guangzhou courts made a landmark ruling on a Class Action Lawsuit against Kangmei Pharmaceutical  This increases the costs of fraud and would boost investor's confidence in China's capital markets
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
chart-bar
x